XOMA Corporation (XOMA) Proxy filing summary

Executive summary

• Announced expected closing of acquisition by Ligand Pharmaceuticals on or about July 14, 2026, pending satisfaction or waiver of closing conditions in the amended Merger Agreement.

• Press release issued regarding the acquisition timeline and related actions, including preferred stock redemption and CVR distribution.

• Forward-looking statements highlight substantial risks and uncertainties related to the acquisition, integration, and regulatory approvals.

Voting matters and shareholder proposals

• Definitive proxy statement filed June 10, 2026, to be mailed to stockholders for voting on the proposed acquisition.

• Stockholders urged to base voting decisions on information in the proxy statement and related SEC filings.

Board of directors and corporate governance

• Board authorized cash dividends and redemption of all outstanding Series A and Series B Preferred Stock in connection with the merger.